Last reviewed · How we verify
Vasopressin administration
Vasopressin administration is a Vasopressin receptor agonist Small molecule drug developed by Assistance Publique Hopitaux De Marseille. It is currently in Phase 3 development for Hemorrhagic shock, Cardiogenic shock, Severe burns.
Vasopressin acts as a potent vasoconstrictor by stimulating V1A receptors on vascular smooth muscle cells, causing blood vessels to constrict.
Vasopressin, a vasopressin V2 receptor agonist, is administered to treat conditions such as nephrogenic diabetes insipidus and lithium-induced nephropathy, as well as to improve concentration ability impaired by lithium treatment. It is also studied as a potential treatment for bipolar disorder and lithium toxicities.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Vasopressin administration |
|---|---|
| Sponsor | Assistance Publique Hopitaux De Marseille |
| Drug class | Vasopressin receptor agonist |
| Target | V1A and V2 receptors |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This leads to increased blood pressure and improved perfusion of vital organs. Vasopressin also has antidiuretic effects by stimulating V2 receptors in the kidneys, reducing water loss in the urine.
Approved indications
- Hemorrhagic shock
- Cardiogenic shock
- Severe burns
Common side effects
- Hypertension
- Nausea
- Headache
Key clinical trials
- DDAVP for Pituitary Adenoma (NA)
- Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial (PHASE3)
- Vitamin D Versus Desmopressin Versus Combination Therapy in Children With Primary Monosymptomatic Nocturnal Enuresis and Vitamin D Deficiency (NA)
- CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial (PHASE2)
- Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal Syndrome (NA)
- Vasopressin vs. Uterine Artery Clamping for Laparoscopic Cesarean Scar Niche Repair (PHASE2)
- Copeptin Concentration Measured in Plasma Samples and Intradialytic Blood Pressure Variation
- Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vasopressin administration CI brief — competitive landscape report
- Vasopressin administration updates RSS · CI watch RSS
- Assistance Publique Hopitaux De Marseille portfolio CI
Frequently asked questions about Vasopressin administration
What is Vasopressin administration?
How does Vasopressin administration work?
What is Vasopressin administration used for?
Who makes Vasopressin administration?
What drug class is Vasopressin administration in?
What development phase is Vasopressin administration in?
What are the side effects of Vasopressin administration?
What does Vasopressin administration target?
Related
- Drug class: All Vasopressin receptor agonist drugs
- Target: All drugs targeting V1A and V2 receptors
- Manufacturer: Assistance Publique Hopitaux De Marseille — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hemorrhagic shock
- Indication: Drugs for Cardiogenic shock
- Indication: Drugs for Severe burns
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing